ASN002 - Emerging Insight and Market Forecast - 2030

ASN002 - Emerging Insight and Market Forecast - 2030

  • February 2021 •
  • 30 pages •
  • Report ID: 6025024 •
  • Format: PDF
“ASN002 - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Chronic Hand Eczema in 7 Major Markets. A detailed picture of the ASN002 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020–2030 is provided in this report along with a detailed description of the product. The product details cover mechanisms of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

ASN002, also known as Gusacitinib is a potent inhibitor of the Janus kinase (JAK) family (JAK1, JAK2, JAK3 and TYK2) and spleen tyrosine kinase (SYK). JAK kinases play a significant role in these inflammatory conditions. SYK is a vital mediator of immunoreceptor signaling in macrophages, neutrophils, mast cells, and B cells. JAK/SYK inhibitors can impact several pathways involved in inflammation of CHE and other dermatologic and inflammatory diseases, thus holding promise as potential therapeutics. Gusacitinib blocks the Th1, Th2, Th17, and Th22 pathways and modulates immunoreceptor signaling in innate immune system cells as well as in keratinocytes. Its ability to target such a broad range of cytokines and cells suggests it would have activity for treating Chronic Hand Eczema (CHE) regardless of its underlying cause.

Scope of the report
The report provides insights into:
? A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
? Elaborated details on regulatory milestones and other development activities have been provided in this report.
? The report also highlights the drug research and development activity details across the United States, Europe and Japan.
? The report also covers the patents information with an expiry timeline around ASN002.
? The report contains forecasted sales for ASN002 till 2030.
? Comprehensive coverage of the Mid-stage emerging therapies (Phase II) for Chronic Hand Eczema.
? The report also features the SWOT analysis with analyst insights and key findings of ASN002.

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ASN002 Analytical Perspective
? In-depth ASN002 Market Assessment
This report provides a detailed market assessment of ASN002 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

? ASN002 Clinical Assessment
The report provides the clinical trials information of ASN002 covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights
? In the coming years, the market scenario for Chronic Hand Eczema is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
? The companies and academics are working to assess challenges and seek opportunities that could influence ASN002 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
? Other emerging products for Chronic Hand Eczema are giving market competition to ASN002 and launch of late-stage emerging therapies in the near future will significantly impact the market.
? A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of ASN002.
? Our in-depth analysis of the forecasted sales data of ASN002 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ASN002.

Key Questions
• Which company is developing ASN002 along with the phase of the clinical study?
• What is the technology utilized in the development of ASN002?
• What is the product type, route of administration and mechanism of action of ASN002?
• What is the clinical trial status of the study and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ASN002 development?
• What are the key designations that have been granted to ASN002?
• What is the forecasted market scenario of ASN002?
• What is the history of ASN002 and what is its future?
• What is the forecasted sales of ASN002 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how these are giving competition to ASN002?
• Which are the late-stage emerging therapies under development for the treatment of the Chronic Hand Eczema?